In the hemophilia A
community, no two patients are the same

When finding a treatment for hemophilia A, your patients' individual needs as well as their lives outside the clinic should be taken into account.1

There are many characteristics that make each patient different1,2:

Different patient characteristics to consider when treating hemophilia A patients are physical activity and lifestyle, bleeding phenotype, pharmacokinetic(PK) profile, infusion dose and frequency, adherence to prophylaxis, annualized bleed rate (ABR) and ABR for joint bleeds, personal goals, and baseline characteristic like age and weight.
  • Physical activity and lifestyle
  • Bleeding phenotype
  • Pharmacokinetic (PK) profile
Different patient characteristics to consider when treating hemophilia A patients are physical activity and lifestyle, bleeding phenotype, pharmacokinetic(PK) profile, infusion dose and frequency, adherence to prophylaxis, annualized bleed rate (ABR) and ABR for joint bleeds, personal goals, and baseline characteristic like age and weight.
  • Infusion dose and frequency
  • Adherence and prophylaxis
  • Annualized bleed rate (ABR) and ABR for joint bleeds
Different patient characteristics to consider when treating hemophilia A patients are physical activity and lifestyle, bleeding phenotype, pharmacokinetic(PK) profile, infusion dose and frequency, adherence to prophylaxis, annualized bleed rate (ABR) and ABR for joint bleeds, personal goals, and baseline characteristic like age and weight.
  • Personal goals
  • Baseline characteristics
    (eg, age, weight)

Living with hemophilia A will always be an undeniable part of their reality—both the welcome and unwelcome moments. Your patients need treatment options that can help them navigate the many complexities of real life with hemophilia A.

Selected Important Risk Information

Warnings & Precautions

Neutralizing antibodies (inhibitors) have been reported following administration of ADVATE predominantly in previously untreated patients (PUPs) and previously minimally treated patients (MTPs). Monitor all patients for the development of factor VIII inhibitors by appropriate clinical observation and laboratory testing. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an expected dose, perform an assay that measures factor VIII inhibitor concentration.

Please see additional detailed important risk information below.

ADVATE has 15+ years of experience treating hemophilia A in the real world3

ADVATE is a third-generation, full-length molecule, similar to the factor VIII that occurs naturally in the body.3,4

ADVATE® [Antihemophilic Factor (Recombinant)] has an established formulation.

Established formulation

with the latest-generation plasma/albumin-free recombinant factor VIII.3,4
ADVATE® [Antihemophilic Factor (Recombinant)] has an established clinical record.

Proven

clinical record.5-7
ADVATE® [Antihemophilic Factor (Recombinant)] is the most widely used factor VIII product.

The most widely used

factor VIII product with 33 billion IUs sold globally.8 Based on units sold, as of February 2019.
ADVATE® [Antihemophilic Factor (Recombinant)] was studied in 15 prospective studies.

Extensively studied

with evidence spanning over 15 years with 15 prospective studies.3,4,8

Committed to advancing hemophilia A care

In 2003, ADVATE became the first recombinant factor VIII treatment free of blood-based additives. Since then, TAKEDA has made advancements with flexible dosing options, reconstitution with BAXJECT® system, and the introduction of myPKFiT® for PK-guided personalized dosing.3,8

2003
ADVATE [Antihemophilic Factor (Recombinant)]: first recombinant factor VIII (rFVIII) made without added human or animal proteins.3,8
2007
First rFVIII 3000-IU single-vial dose.8
2011
First and only rFVIII with physical health-related quality-of-life results in the Prescribing Information.3
2014
ADVATE with BAXJECT III® reconstitution system.8
2006
BAXJECT II needleless transfer device.8
2010
First and only rFVIII 1700-IU single-vial dose.8
2012
First and only rFVIII 4000-IU single-vial dose and 2-mL diluent option (250 IU, 375 IU, 500 IU, 750 IU, 1000 IU, 1500 IU, and 1700 IU).3,8
2018
myPKFiT for ADVATE receives approval from the FDA for patients 16 and older.8
ADVATE has an established safety profile
See the data
See ADVATE prophylaxis study results
Learn more
  1. Valentino LA. Considerations in individualizing prophylaxis in patients with haemophilia A. Haemophilia. 2014;20(5):6
  2. Petrini P, Valentino LA, Gringeri A, Re WM, Ewenstein B. Individualizing prophylaxis in hemophilia: a review. Expert Rev Hematol. 2015;8(2):237-246. doi:10.1586/17474086.2015.1002465
  3. Advate. Prescribing information. Baxalta US Inc; 2018.
  4. Grillberger L, Kreil TR, Nasr S, Reiter M. Emerging trends in plasma-free manufacturing of recombinant protein therapeutics expressed in mammalian cells. Biotechnol J. 2009;4(2):186-201. doi:10.1002/biot.200800241
  5. Auerswald G, Thompson AA, Recht M, et al. Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A. Thromb Haemost. 2012;107(6):1072-1082. doi:10.1160/TH11-09-0642
  6. Khair K, Mazzucconi MG, Parra R, et al. Pattern of bleeding in a large prospective cohort of haemophilia A patients: a three-year follow-up of the AHEAD (Advate in HaEmophilia A outcome Database) study. Haemophilia. 2018;24(1):85-96. doi:10.1111/hae.13361
  7. Valentino LA, Mamonov V, Hellmann A, et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost. 2012;10(3):359-367. Published correction appears in J Thromb Haemost. 2012;10(6):1204.
  8. Takeda data on file.